The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
about
Biologic safety in psoriasis: review of long-term safety data.Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsThe Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.Long-term safety of ustekinumab for psoriasis.Biological therapies for psoriasis.Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists.Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations.Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab.Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.Biologics in dermatology: adverse effects.Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis.Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential.A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial.Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?Biologic treatments for elderly patients with psoriasis.Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.Assessment and monitoring of biologic drug adverse events in patients with psoriasis.Ustekinumab (Stelara®1)2Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
P2860
Q30904076-BA4A361F-E559-4346-AF54-2A4D8ECD0048Q33800651-36FE9C1B-2929-483F-9F07-0DCBE7C07182Q33809045-76B7941B-FFF2-44BC-BAD5-44BEE81718B3Q35840998-46A77791-1172-4456-BB46-2845E536AAF5Q38112783-19399FAB-8CF9-4715-AB16-35A3A78A3F93Q38155648-2720A1BF-EF5F-4497-B750-BB8560EE45EEQ38411930-A5B12619-5033-4C46-9CDE-E63CE397E74DQ38712213-071FB032-61EE-418D-8DA3-8CAD02CC22C3Q38727735-49355554-72F8-4EA6-B691-3AA604F601D2Q38749257-00CA84B4-0B42-4C32-9DC8-D26F46EBB761Q39084627-30164D6D-6AC3-4600-AD7D-754A8D217EEFQ40060286-BED60E40-1781-42D5-BADA-A2D3F76BED52Q40800468-8D130070-9556-44D0-8403-DD71BE0CD9E4Q41120913-EECF1E49-9CC2-432A-8984-C500AFDF4A64Q41688405-F4428006-7633-4817-A64E-536002343FCBQ42956548-3367D2EA-0F86-4725-A4B8-6ECE0FE1CB43Q43560572-7D792338-0635-4BD3-B470-E3342DDC5504Q46247849-7C60CDA5-531D-458A-AB0A-10D447519948Q48236525-02C8BDF1-1C53-4BED-A03D-568128B9E8F7Q53841352-6A8ABB01-4EA3-4AC3-AFAA-E7828C0E1B34Q55153984-162D7543-747C-406B-A409-D36F18101A21Q58008027-66DCD8CD-33F7-4F24-B05E-D993AA5269C4Q58720009-CB597902-E5FF-42EA-861B-4833E2539F0E
P2860
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
The safety of ustekinumab trea ...... latent tuberculosis infection.
@en
The safety of ustekinumab trea ...... latent tuberculosis infection.
@nl
type
label
The safety of ustekinumab trea ...... latent tuberculosis infection.
@en
The safety of ustekinumab trea ...... latent tuberculosis infection.
@nl
prefLabel
The safety of ustekinumab trea ...... latent tuberculosis infection.
@en
The safety of ustekinumab trea ...... latent tuberculosis infection.
@nl
P2093
P2860
P1476
The safety of ustekinumab trea ...... latent tuberculosis infection.
@en
P2093
C Leonardi
PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups
P2860
P304
P356
10.1111/J.1365-2133.2012.11142.X
P407
P577
2012-11-01T00:00:00Z